Skip to main content
Article thumbnail
Location of Repository

Clinical and Practical Perspectives on the Use of Intravenous vs.

By Nancy A. Mason, Pharmd Wendy L. St. Peter, George R. Bailie, Phd Curtis, A. Johnson and Subcutaneous Epoetin


This work was supported by an educational grant from Amgen, Inc. The content and opinions expressed in this article are those of the authors alone. Background. The route of Epoetin alfa (EPO) administration has become a controversial issue in recent years. Despite the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) guidelines recommending subcutaneous (SC) EPO for all dialysis patients, only 12 % of hemodialysis patients in the U.S. receive EPO by the SC route. Methods. A telephone survey was undertaken to gather opinions and clinical practice information regarding the choice of EPO route of administration. Sixteen people from several different vantage points within the dialysis community were interviewed about a variety of factors related to route of EPO therapy including clinical outcomes, financial aspects, impact on staff workload, and patient preferences. Six interviewees were specifically chosen to represent programs i

Topics: Arbor, MI, Dr. St. Peter is
Year: 2011
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.